[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anaptysbio Inc (ANAB)

Anaptysbio Inc (ANAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,908,443
  • Shares Outstanding, K 29,101
  • Annual Sales, $ 234,600 K
  • Annual Income, $ -13,230 K
  • EBIT $ 48 M
  • EBITDA $ 46 M
  • 60-Month Beta 0.79
  • Price/Sales 8.43
  • Price/Cash Flow N/A
  • Price/Book 50.54

Options Overview Details

View History
  • Implied Volatility 94.12% (+7.56%)
  • Historical Volatility 77.77%
  • IV Percentile 71%
  • IV Rank 33.94%
  • IV High 161.61% on 09/24/25
  • IV Low 59.45% on 12/22/25
  • Expected Move (DTE 2) 6.95 (11.09%)
  • Put/Call Vol Ratio 3.12
  • Today's Volume 239
  • Volume Avg (30-Day) 272
  • Put/Call OI Ratio 4.29
  • Today's Open Interest 5,633
  • Open Int (30-Day) 3,328
  • Expected Range 55.74 to 69.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.32
  • Number of Estimates 3
  • High Estimate $-0.07
  • Low Estimate $-0.54
  • Prior Year $-1.34
  • Growth Rate Est. (year over year) +76.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.79 +43.14%
on 04/17/26
72.36 -13.37%
on 05/05/26
+16.86 (+36.81%)
since 04/13/26
3-Month
35.12 +78.49%
on 03/03/26
72.36 -13.37%
on 05/05/26
+27.30 (+77.14%)
since 02/13/26
52-Week
11.40 +449.67%
on 09/16/25
72.36 -13.37%
on 05/05/26
+49.01 (+358.22%)
since 05/13/25

Most Recent Stories

More News
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda...

ANAB : 62.69 (-4.41%)
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

Strengthens Leadership Team and Board with additional business development, finance and royalty management expertise SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a...

ANAB : 62.69 (-4.41%)
AnaptysBio's Royalty Stream Prints Cash but the Pipeline Still Burns It

Barchart Research What to Expect from ANAB Earnings ANAB Generated May 8, 2026 Current Price $69.33 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Stream Prints...

ANAB : 62.69 (-4.41%)
AnaptysBio's Royalty Stream Prints Cash but the Pipeline Still Burns It

Barchart Research What to Expect from ANAB Earnings ANAB Generated May 8, 2026 Current Price $69.33 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Stream Prints...

ANAB : 62.69 (-4.41%)
AnaptysBio's Royalty Stream Prints Cash but the Pipeline Still Burns It

Barchart Research What to Expect from ANAB Earnings ANAB Generated May 8, 2026 Current Price $69.33 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Stream Prints...

ANAB : 62.69 (-4.41%)
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for  Jemperli with GSK and imsidolimab with Vanda, today announced...

ANAB : 62.69 (-4.41%)
AnaptysBio's Royalty Cash Machine Looks Bulletproof but the Pipeline Spin-Off Creates New Questions

Barchart Research What to Expect from ANAB Earnings ANAB Generated May 1, 2026 Current Price $66.76 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Cash Machine...

ANAB : 62.69 (-4.41%)
AnaptysBio's Royalty Cash Machine Looks Bulletproof but the Pipeline Spin-Off Creates New Questions

Barchart Research What to Expect from ANAB Earnings ANAB Generated May 1, 2026 Current Price $66.76 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Cash Machine...

ANAB : 62.69 (-4.41%)
AnaptysBio's Royalty Cash Machine Looks Bulletproof but the Pipeline Spin-Off Creates New Questions

Barchart Research What to Expect from ANAB Earnings ANAB Generated May 1, 2026 Current Price $66.76 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Cash Machine...

ANAB : 62.69 (-4.41%)
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

WASHINGTON , April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab...

ANAB : 62.69 (-4.41%)
VNDA : 6.43 (+0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

See More

Key Turning Points

3rd Resistance Point 73.16
2nd Resistance Point 69.13
1st Resistance Point 65.91
Last Price 62.69
1st Support Level 58.66
2nd Support Level 54.63
3rd Support Level 51.41

See More

52-Week High 72.36
Last Price 62.69
Fibonacci 61.8% 49.07
Fibonacci 50% 41.88
Fibonacci 38.2% 34.69
52-Week Low 11.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.